Exosome Diagnostic And Therapeutic Market Report 2026

Exosome Diagnostic And Therapeutic Market Overview

• Exosome Diagnostic And Therapeutic market size has reached to $0.6 billion in 2025 • Expected to grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 28% • Growth Driver: Exosome Diagnostics And Therapeutics Market Driven By Increasing Prevalence Of Chronic Diseases • Market Trend: Innovative Solutions In The Exosome Diagnostic And Therapeutic Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Exosome Diagnostic And Therapeutic Market?

Exosome diagnostics and therapeutic refer to using exosomes, tiny extracellular particles generated by cells, in diagnosis and therapy. Exosomes are used in exosome therapies as a method of targeted medication delivery for regenerative medicine. The main products of the exosome diagnostic and therapeutic market are instruments, software, reagents, and kits. An instrument refers to equipment or instruments used to carry out activities or experiments precisely and accurately. These are used in various applications such as diagnostics and therapeutics and also by various end users such as academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and others.

What Is The Exosome Diagnostic And Therapeutic Market Growth Forecast?

The exosome diagnostic and therapeutic market size is expected to see exponential growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 28.0%. The growth in the forecast period can be attributed to increasing clinical translation of exosome therapies, rising demand for personalized medicine solutions, expansion of ai-enabled exosome data analysis, growing pharmaceutical interest in biologic delivery systems, increasing regulatory clarity for advanced therapies. Major trends in the forecast period include increasing use of exosomes for targeted drug delivery, rising adoption of liquid biopsy diagnostics, growing demand for regenerative medicine applications, expansion of advanced exosome isolation technologies, enhanced focus on precision therapeutic development.

What Is The Driver Of The Exosome Diagnostic And Therapeutic Market?

The rising prevalence of chronic diseases is expected to propel the growth of the exosome diagnostic and therapeutic market going forward. Chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Diagnostic and therapeutic applications of exosomes act as possible biomarkers in cancer that provide more sensitive disease monitoring, making personalized medicine more reachable. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, there will be 142.66 million people with chronic diseases worldwide by the year 2050. Therefore, the rising prevalence of chronic diseases is driving the exosome diagnostics and therapeutics market.

Key Players In The Global Exosome Diagnostic And Therapeutic Market

Major companies operating in the exosome diagnostic and therapeutic market are Thermo Fisher Scientific Inc., Miltenyi Biotec GmbH, Malvern Instruments Inc., System Biosciences LLC, NanoSomix Inc., Exosome Diagnostics Inc., Evox Therapeutics Ltd., ExCoBio Inc., Codiak BioSciences Inc., Capricor Therapeutics Inc., Aethlon Medical Inc., NX Pharmagen Inc., Aegle Therapeutic Corporation, Ciloa, Sistemic Inc., Theoria Science, Mantra Bio Inc., Lonza Group AG, Bio-Techne Corp.

Global Exosome Diagnostic And Therapeutic Market Trends and Insights

Major companies operating in the exosome diagnostic and therapeutic market are developing innovative products, such as sample purification systems, to meet larger customer bases, increase sales, and increase revenue. A sample purification system is a set of processes and technologies designed to remove impurities and contaminants from a sample, such as DNA, RNA, proteins, or other biomolecules. For instance, in February 2023, Biological Dynamics Inc., a US-based biotechnology company, launched ExoVerita, an exosome-isolation platform for early disease surveillance and other applications. The ExoVita Pancreas assay detects particular exosomal protein indicators and has been shown to detect Stage 1 and Stage 2 pancreatic ductal adenoma carcinoma (PDAC) using blood-based exosome samples enriched on the patented ExoVerita apparatus. The company will use this validation to test samples from the ExoLuminate registry trial (NCT05625529), which has started actively recruiting patients with high-risk PDAC to examine the test's clinical value. Patients with clinical signs such as pancreatitis or known pancreatic lesions, individuals with a genetic or familial propensity, and newly diagnosed diabetics over 50 are also eligible.

What Are Latest Mergers And Acquisitions In The Exosome Diagnostic And Therapeutic Market?

In June 2023, Evox Therapeutics Ltd., a UK-based biotechnology company, acquired Codiak Biosciences' engEx-AAV technology platform for an undisclosed amount. The acquisition's aim is to leverage the engEx-AAV technology to enhance exosome-mediated delivery systems, thereby advancing the development of innovative gene therapies and genome editors. This strategic move is designed to strengthen Evox Therapeutics' capabilities in creating effective genetic medicines. Codiak Biosciences is a US-based biopharmaceutical company that specializes in the development of exosome-based therapeutics.

What Defines the Exosome Diagnostic And Therapeutic Market?

The exosome diagnostic and therapeutic market consists of revenues earned by entities by providing services such as genomic sequencing, exome sequencing, resequencing, and targeted sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The exosome diagnostic and therapeutic market also includes sales of exosome-based assays, exosome flow cytometry kits, and protein biomarker detection kits, which are used in providing exosome-based drug delivery services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Exosome Diagnostic And Therapeutic Market Report 2026?

The exosome diagnostic and therapeutic market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the exosome diagnostic and therapeutic industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.